Raymond James Financial Services Advisors Inc. raised its stake in shares of Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE – Get Rating) by 225.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,489 shares of the company’s stock after purchasing an additional 10,039 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Invesco Dynamic Biotechnology & Genome ETF were worth $854,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of PBE. Adirondack Trust Co. acquired a new position in Invesco Dynamic Biotechnology & Genome ETF during the 3rd quarter valued at approximately $41,000. Atria Wealth Solutions Inc. purchased a new stake in shares of Invesco Dynamic Biotechnology & Genome ETF in the 1st quarter valued at $221,000. Strategic Blueprint LLC purchased a new stake in shares of Invesco Dynamic Biotechnology & Genome ETF in the 2nd quarter valued at $291,000. Carnegie Capital Asset Management LLC boosted its holdings in shares of Invesco Dynamic Biotechnology & Genome ETF by 5.2% in the 2nd quarter. Carnegie Capital Asset Management LLC now owns 4,015 shares of the company’s stock valued at $311,000 after acquiring an additional 200 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of Invesco Dynamic Biotechnology & Genome ETF by 153.4% in the 2nd quarter. Citadel Advisors LLC now owns 10,843 shares of the company’s stock valued at $626,000 after acquiring an additional 6,564 shares during the last quarter.
Invesco Dynamic Biotechnology & Genome ETF Stock Up 1.3 %
PBE stock opened at $67.25 on Monday. The firm’s fifty day simple moving average is $65.00 and its 200-day simple moving average is $62.88. Invesco Dynamic Biotechnology & Genome ETF has a 12 month low of $51.39 and a 12 month high of $68.11.
Invesco Dynamic Biotechnology & Genome ETF Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.
Read More
- Get a free copy of the StockNews.com research report on Invesco Dynamic Biotechnology & Genome ETF (PBE)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE – Get Rating).
Receive News & Ratings for Invesco Dynamic Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Dynamic Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.